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Bioresorbable scaffolds, of which most experience has been obtained with the poly-L-lactide (PLLA)-
based Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara, CA, USA), have 
the potential to overcome the limitations of metallic drug-eluting stents (DES), as they temporarily 
scaffold the diseased coronary vessel and then disappear. After degradation of the BVS, the 
coronary artery can restore its vasomotion and it may show favourable vascular remodelling11. Iqbal 
J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: rationale, 
current status, challenges, and future. Eur Heart J. 2014;35:765-76. ,22. Serruys PW, Chevalier B, 
Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, 
Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A 
bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic 
heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year 
analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 
2015;385:43-54. ,33. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt 
MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW; 
ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. 
N Engl J Med. 2015;373:1905-15. . During the last four years, more than 100,000 patients have 
been treated with BVS, while several million patients have been treated with metallic DES which 
showed favourable clinical outcomes in randomised clinical trials, including low target vessel 
revascularisation and stent thrombosis rates44. Serruys PW, Silber S, Garg S, van Geuns RJ, 
Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, 
Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, 
Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-
eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-46. ,55. von Birgelen C, 
Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin 
RM, Louwerenburg JW, de Man FH, Stoel MG, Lowik MM, Linssen GC, Said SA, Nienhuis MB, 
Verhorst PM, Basalus MW, Doggen CJ, Tandjung K. Third-generation zotarolimus-eluting and 
everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention 
(DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 
2014;383:413-23. . So why has there not been a surge in the use of BVS in our daily clinical 
practice? A simple but important reason is the efficacy and proven long-term safety of the current-
generation DES. When we recall the introduction of bare metal stents and – more than a decade 
later – DES, there were compelling reasons to introduce these devices rapidly, as in both cases the 
new devices solved or mitigated major clinical problems, for which there was no similarly effective 
alternative. BVS promise to overcome the problem of neoatherosclerosis formation in DES, which 
has been observed in both early and newer-generation DES66. Otsuka F, Vorpahl M, Nakano M, 
Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, Virmani R. Pathology of 
second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting 
stents in humans. Circulation. 2014;129:211-23. ; however, considering the relatively low long-term 
event rates of patients treated with modern DES, this problem seems to be not overly common. The 
benefits of BVS are presumed to pay off in lower event rates after several years, but this remains to 
be demonstrated in ongoing large trials. While patients of all ages intuitively embrace the concept of 
a dissolving device, one may expect to see the greatest potential clinical benefit in the young and 
middle-aged. In addition, recent clinical studies and meta-analyses have shown some signals of a 
potential increase in risk of (early) stent thrombosis with bioresorbable scaffolds77. Capodanno D, 
Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, 
Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, 
Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular 
scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre 
GHOST-EU registry. EuroIntervention. 2015;10:1144-53. ,88. Cassese S, Byrne RA, Ndrepepa G, 
Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T, Kastrati A. Everolimus-eluting 
bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of 
randomised controlled trials. Lancet. 2016;387:537-44. ,99. Kolandaivelu K, Swaminathan R, Gibson 
WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. 
Stent thrombogenicity early in high-risk interventional settings is driven by stent design and 
deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-9. . While the 
significance of this finding is still unclear, the timing of scaffold thrombosis, early after implantation, 
suggests a relation with the relatively thick strut dimensions, the apposition to the vessel wall, and/or 
implantation techniques (e.g., aggressiveness of lesion preparation, adequate device sizing with or 
without intracoronary imaging, employment of post-dilatation, balloon size and pressures used). For 
thick-strut coronary stents and scaffolds alike, it is of paramount importance to appose the device 
well to the vessel wall99. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-
Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in 
high-risk interventional settings is driven by stent design and deployment and protected by polymer-
drug coatings. Circulation. 2011;123:1400-9. . In clinical practice, there is frequently a need for stent 
post-dilatation and overexpansion to achieve full device apposition1010. Basalus MW, van 
Houwelingen KG, Ankone MJ, Feijen J, von Birgelen C. Micro-computed tomographic assessment 
following extremely oversized partial postdilatation of drug-eluting stents. EuroIntervention. 
2010;6:141-8. , and the same holds true for BVS. Severely oversized post-dilatations of metallic 
stents are generally well tolerated without destructive consequences to the metal frame, but may 
have a significant effect on stent geometry1010. Basalus MW, van Houwelingen KG, Ankone MJ, 
Feijen J, von Birgelen C. Micro-computed tomographic assessment following extremely oversized 
partial postdilatation of drug-eluting stents. EuroIntervention. 2010;6:141-8. . The consequences of 
BVS overexpansion have not been fully examined, so it was high time that a thorough evaluation of 
this matter was performed and published. In the current issue of EuroIntervention, Foin et al report 
the results of meticulous bench-top experiments on the overexpansion of BVS with non-compliant 
balloons of increasing diameters1111. Foin N, Lee R, Mattesini A, Caiazzo G, Fabris E, Kilic D, 
Chan JN, Huang Y, Venkatraman SS, Di Mario C, Wong P, Nef H. Bioabsorbable vascular scaffold 
overexpansion: insights from in vitro post-expansion experiments. EuroIntervention. 2016;11:1389-
99. . While BVS of different sizes could be oversized by 1 mm in a non-constrained setting, only 
overexpansion with a non-compliant balloon 0.5 mm larger than the BVS size was feasible in a 
constraining eccentric arterial lesion model. Excessive overexpansion of BVS beyond that limit 
resulted in scaffold fractures and a decrease in mechanical support, as impressively demonstrated 
by mechanical point force measurements. This loss of mechanical support may trigger adverse 
clinical events. The work of Foin et al confirms the “no more than 0.5 mm larger” instruction for BVS 
post-dilatation with non-compliant balloons which was provided by the device manufacturer. In 
addition, interesting insights with 2D and 3D optical coherence tomography (OCT) in fractured BVS 
samples demonstrated an advantage of 3D OCT in detecting fracture sites. Partial overexpansion of 
BVS with non-compliant balloons beyond the safety limit of 0.5 mm resulted in fractures which were 
located, in particular, in the region between the post-dilated and non-post-dilated segments1111. 
Foin N, Lee R, Mattesini A, Caiazzo G, Fabris E, Kilic D, Chan JN, Huang Y, Venkatraman SS, Di 
Mario C, Wong P, Nef H. Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-
expansion experiments. EuroIntervention. 2016;11:1389-99. . In parallel with these findings, 
previous studies of metallic DES demonstrated the greatest stent deformation to be present just in 
that region (Figure 1)1010. Basalus MW, van Houwelingen KG, Ankone MJ, Feijen J, von Birgelen 
C. Micro-computed tomographic assessment following extremely oversized partial postdilatation of 
drug-eluting stents. EuroIntervention. 2010;6:141-8. . Figure 1. Micro-computed tomographic 
assessment following extremely oversized partial post-dilatation of metallic DES with an open-cell 
design. The maximum stent deformation with the largest cells (arrowheads) was seen in the 
transitional region between the 1.5 mm overexpanded and the non-post-dilated segments (A: 
TAXUS Liberté™; Boston Scientific, Natick, MA, USA; B: Resolute™; Medtronic, Santa Rosa, CA, 
USA). The region of maximum stent deformation corresponds with the scaffold region in the study by 
Foin et al1111. Foin N, Lee R, Mattesini A, Caiazzo G, Fabris E, Kilic D, Chan JN, Huang Y, 
Venkatraman SS, Di Mario C, Wong P, Nef H. Bioabsorbable vascular scaffold overexpansion: 
insights from in vitro post-expansion experiments. EuroIntervention. 2016;11:1389-99. which showed 
many BVS fractures after excessive partial overexpansion. Quantitative data on DES deformation 
have previously been reported1010. Basalus MW, van Houwelingen KG, Ankone MJ, Feijen J, von 
Birgelen C. Micro-computed tomographic assessment following extremely oversized partial 
postdilatation of drug-eluting stents. EuroIntervention. 2010;6:141-8. . The safety limit of BVS 
overexpansion emphasises the fact that an optimised sizing of BVS is of paramount importance. In a 
way, this is an echo from the past, when intravascular ultrasound (IVUS) measurements taught the 
interventional community that bare metal stents had to be implanted and often post-dilated with 
larger balloons and at higher pressures to improve stent expansion and apposition1212. Colombo A, 
Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. 
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. 
Circulation. 1995;91:1676-88. ,1313. von Birgelen C, Gil R, Ruygrok P, Prati F, Di Mario C, van der 
Giessen WJ, de Feyter PJ, Serruys PW. Optimized expansion of the Wallstent compared with the 
Palmaz-Schatz stent: on-line observations with two- and three-dimensional intracoronary ultrasound 
after angiographic guidance. Am Heart J. 1996;131: 1067-75. . IVUS use then resulted in an 
impressive reduction of stent thrombosis risk1212. Colombo A, Hall P, Nakamura S, Almagor Y, 
Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without 
anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-88. 
. Careful pre-interventional assessment of reference vessel size and examinations of BVS implanted 
are likely to improve the clinical results in BVS too. In most of the recent BVS studies, quantitative 
coronary angiography was used for BVS sizing, but in some studies IVUS was also performed22. 
Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, 
Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, 
Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for 
ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 
1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. 
Lancet. 2015;385:43-54. . Pre-interventional IVUS can be highly valuable for the assessment of true 
vessel size and both vascular remodelling and tapering1414. von Birgelen C, Mintz GS, de Vrey EA, 
Kimura T, Popma JJ, Airiian SG, Leon MB, Nobuyoshi M, Serruys PW, de Feyter PJ. Atherosclerotic 
coronary lesions with inadequate compensatory enlargement have smaller plaque and vessel 
volumes: observations with three dimensional intravascular ultrasound in vivo. Heart. 1998;79:137-
42. . Imaging with OCT can also help to optimise BVS safely and to detect device fractures, which –
of course– should be prevented based on pre-interventional measurements of vessel size1111. Foin 
N, Lee R, Mattesini A, Caiazzo G, Fabris E, Kilic D, Chan JN, Huang Y, Venkatraman SS, Di Mario 
C, Wong P, Nef H. Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-
expansion experiments. EuroIntervention. 2016;11:1389-99. ,1515. Allahwala UK, Cockburn JA, 
Shaw E, Figtree GA, Hansen PS, Bhindi R. Clinical utility of optical coherence tomography (OCT) in 
the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous 
coronary intervention. EuroIntervention. 2015;10:1154-9. . Does the current study provide answers 
to all relevant questions about the overexpansion of bioresorbable scaffolds? Well, probably not. 
While the authors obtained highly valuable data about Absorb BVS, they did not study other 
polymer- or magnesium-based bioresorbable scaffolds which have different physical properties1616. 
Ormiston J, Webber B, Ubod B, Darremont O, Webster MW. An independent bench comparison of 
two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic 
drug-eluting stent (ML8/Xpedition). EuroIntervention. 2015;11:60-7. ,1717. Haude M, Ince H, Abizaid 
A, Toelg R, Lemos PA, von Birgelen C, Christiansen EH, Wijns W, Neumann FJ, Kaiser C, Eeckhout 
E, Lim ST, Escaned J, Garcia-Garcia HM, Waksman R. Safety and performance of the second-
generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions 
(BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. 
Lancet. 2016;387:31-9. . For instance, a PLLA-based scaffold, which regains its diameter after acute 
recoil due to the “self-correcting” properties of the device, was previously shown to have a much 
greater tolerance to significantly oversized post-dilations than the Absorb BVS1616. Ormiston J, 
Webber B, Ubod B, Darremont O, Webster MW. An independent bench comparison of two 
bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-
eluting stent (ML8/Xpedition). EuroIntervention. 2015;11:60-7. . Finally, Foin et al used expired BVS 
for their experiments, and polymer ageing could have affected the physical properties of the devices 
tested1818. Bergström JS, Hayman D. An Overview of Mechanical Properties and Material Modeling 
of Polylactide (PLA) for Medical Applications. Ann Biomed Eng. 2015 Sep 14. [Epub ahead of print]. 
. Therefore, it would be of great interest to perform additional in vitro studies with fresh samples of 
the Absorb BVS and other bioresorbable scaffolds, using the same experimental set-up as applied in 
the current study. To conclude, well-controlled post-dilatation and overexpansion of current BVS is 
likely to prevent a substantial proportion of potential scaffold thromboses by improving the BVS 
apposition to the vessel wall. On the other hand, excessive overexpansion can lead to fractures of 
the polymer that may induce adverse events such as scaffold thromboses. 3D OCT, a technique 
which Foin et al used in their current bench-top study to identify BVS fractures, could not only help 
reveal the mechanisms of thrombus formation in BVS, but has – together with IVUS and other 
advanced quantitative coronary imaging techniques – the potential to reduce the risk of fracturing 
struts - See more at: http://www.pcronline.com/eurointervention/95th_issue/volume-11/number-
12/259/oversized-post-dilatation-of-current-bioresorbable-vascular-scaffolds-kill-or-cure. 
